Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Ligand Pharmaceuticals (LGND)

Ligand Closes $460.0 Million 0.75% Convertible Notes Offering Due 2030

Neutral Impact 3 of 5 financing Written later

Ligand Pharmaceuticals completed a private offering of $460.0 million of 0.75% convertible senior notes due October 1, 2030, including the full exercise of a $60.0 million option, with net proceeds of approximately $445.1 million. The notes are unsecured senior obligations, so the offering adds a new debt obligation for shareholders to weigh, while the company says convertible note hedges are expected generally to reduce potential dilution from conversions.

Key points

  • $460.0 million aggregate principal at 0.75% interest, payable semiannually from April 1, 2026; maturity October 1, 2030
  • Initial conversion price of approximately $194.79 per share, a premium of approximately 32.5% to the August 11, 2025 last reported sale price
  • Net proceeds of approximately $445.1 million; about $45.9 million used for hedge costs and $15.0 million to repurchase 102,034 shares at $147.01 per share
  • Warrants have an initial strike price of $294.02 per share and could have a dilutive effect if the stock price exceeds that level; the company may not redeem the notes before October 6, 2028

The filing

CompanyLigand Pharmaceuticals (LGND)
Form8-K, current report
Filed with the SECAug 14, 2025, 4:41 PM ET
Accession number0001193125-25-180841

Items reported: 1.01 Material Definitive Agreement2.03 New Direct Financial Obligation3.02 Unregistered Equity Sale8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 14, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.